Payment overview · 2025
General Payments
$70.86
4 reported records · 3 companies
Healthcare provider profile · identity verified
Bindu Alex Antony
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CHERRY HILL, NJ · NPI 1982114674
Verified facts
What the public records show
CMS Open Payments records show Bindu Alex Antony received $70.86 in general payments during 2025 across 4 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 44.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Vraylar by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $31.46 | 44.4% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $21.38 | 30.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.02 | 25.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $70.86 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $15.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 70 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lorazepam | Lorazepam | 507 | 13 |
| Atorvastatin Calcium | Atorvastatin Calcium | 186 | 18 |
| Clonazepam | Clonazepam | 116 | suppressed |
| Risperidone | Risperidone | 95 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 84 | suppressed |
| Omeprazole | Omeprazole | 84 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 77 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 76 | suppressed |
| Vraylar | Cariprazine Hcl | 70 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 67 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 64 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 60 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 58 | suppressed |
| Famotidine | Famotidine | 56 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 54 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 53 | suppressed |
| Levetiracetam | Levetiracetam | 53 | suppressed |
| Finasteride | Finasteride | 50 | suppressed |
| Lactulose | Lactulose | 43 | suppressed |
| Eliquis | Apixaban | 42 | suppressed |
| Losartan Potassium | Losartan Potassium | 38 | suppressed |
| Metformin Hcl | Metformin Hcl | 31 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 31 | 16 |
| Icosapent Ethyl | Icosapent Ethyl | 30 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 29 | suppressed |
| Haloperidol | Haloperidol | 29 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Gabapentin | Gabapentin | 28 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 26 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Simvastatin | Simvastatin | 23 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 21 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Triazolam | Triazolam | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 16 | suppressed |
| Austedo | Deutetrabenazine | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Daptomycin | Daptomycin | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Prolia | Denosumab | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Clobazam | Clobazam | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Ramelteon | Ramelteon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $70.86 · 4 records | Teva Pharmaceuticals USA, Inc. | AUSTEDO XR, Fintepla, UZEDY, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error